Dr. Dirk Arnold on Sirflox and its Effect on Liver Metastases
Dirk Arnold, MD, PhD, Professor and Head Dept. Hematology and Medical Oncology at Tumor Biology Center in Freiburg, Germany, talks about sirflox and its phase III trials on whether or not it can properly add local ablative treatment to diffuse metastasization of the liver.
Dirk Arnold, MD, PhD, Professor and Head Dept. Hematology and Medical Oncology at Tumor Biology Center in Freiburg, Germany, talks about Sirflox, its phase III trials, and whether or not it can properly add local ablative treatment to diffuse metastasization of the liver.
Arnold calls the results of the study surprising. He says that while the progression-free survival in the liver turned out to be impressive, the overall progression-free survival of patients that participated in the study were not nearly as good.
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
